Celgene (CELG) Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed AML Met Primary and Key Secondary Endpoints
September 12, 2019 4:30 PM
Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
